International Psoriasis Council

subscribe
Search

Advancing Knowledge. Enhancing Care.

subscribe
Search

Advancing Knowledge. Enhancing Care.

Dermavant Announces FDA Approval for VTAMA® (Tapinarof) Cream

Dermavant news
Dermavant Sciences announced that VTAMA® (tapinarof) cream, 1%, an aryl hydrocarbon receptor agonist, indicated for the topical treatment of plaque psoriasis in adults, has been approved by the U.S. Food and Drug Administration (FDA). VTAMA® cream provides efficacy over 52 weeks and is well-tolerated on the most sensitive skin areas. This approval makes VTAMA® cream the first and only FDA-approved non-steroid topical medication for adults living with plaque psoriasis. The product is expected to be available beginning June 2022.
Read Full Press Release
Dermavant Sciences, a subsidiary of Roivant Sciences

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Categories

Recent Posts

Getting to Know IPC’s Board Member Claudia de la Cruz: What Inspired Me to Specialize in Psoriasis

VIEW

Introducing Our Latest IPC Councilors: Experts in Psoriasis Treatment and Research

VIEW

Shining a Spotlight: Catching up with 2018 IPC Fellow, Jia Qi Chen, PhD

VIEW

Also Read
TYK2 inhibitors

Focus on Psoriasis: A Report from the 32nd European Academy of Dermatology and Venereology 2023 Congress (EADV)

Access the latest insights from the 32nd European Academy of Dermatology and Venereology 2023 Congress (EADV) in Berlin, Germany. This report covers significant updates on psoriasis, including the International Psoriasis Council’s Symposium and late-breaking sessions. Download the full EADV Congress Report for a comprehensive overview of psoriasis presentation and treatment advancements.

Read More
Monday, November 27, 2023
Blog - Commentary - Alexander Egeberg - graphic
intravenous approval

Commentary: Looking Beyond Plaque Psoriasis: Novel IL-36 Inhibitor for Prevention of Generalized Pustular Psoriasis Flares

Discover the latest in generalized pustular psoriasis (GPP) treatment with the approval of intravenous spesolimab by regulatory authorities. Read about a 48-week study on the subcutaneous delivery of spesolimab, showcasing promising results for preventing GPP flares. Learn about the evolving landscape of GPP treatment.

Read More
Monday, November 20, 2023

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.
Subscribe
Click this image to register for IPC's free global webinar. This webinar takes place Wednesday, December 13 from 12:30 - 13:30 CET.